Skin Longevity Skincare: Exosomes, PDRN, and Epigenetic Innovation
Clinical Summary
Skin Longevity Technologies: Polynucleotides, Exosomes, and Epigenetic Modulation
-
Emerging regenerative technologies: PDRN/polynucleotides, exosomes, and epigenetic-targeting ingredients are already entering clinical practice; innovations include bacterial-derived PDRN and plant-derived exosomes, which may improve scalability and regulatory feasibility.
-
Safety & clinician oversight: With limited FDA oversight of biologically active skincare ingredients, dermatologists and professional societies must help define safety standards, clinical protocols, and evidence-based pathways for adoption.
-
Future paradigm shift: Anti-aging is evolving toward a “skin longevity” model, emphasizing epigenetic modulation, telomere preservation, and cellular signaling optimization with new biomarkers/endpoints focused on long-term skin function and healthspan.
Reviewed by Riya Gandhi, MA, Associate Editor of Immunology Group
Dr Ted Lain discusses emerging skincare innovations, including polynucleotides, exosomes, and epigenetic-targeting ingredients, and how they may shape the future of skin longevity. Learn how dermatologists can evaluate biologically active skincare technologies, prioritize safety, and move beyond “anti-aging” toward evidence-based regenerative and longevity-focused skin health.
TRANSCRIPT
Hi, I'm Dr Ted Lain. I'm a board-certified dermatologist. I practice in Austin, Texas.
With emerging innovations like polynucleotides, exosomes, and epigenetic-targeting ingredients, which technologies do you believe are closest to meaningful clinical application?
Dr Lain: I think all those technologies are really close to meaningful application in clinical practice, I mean, they're all really being used right now. I think they're being optimized, though, so, for example, PDRN historically has been derived from fish, so it's animal-based, but we're now starting to see some bacterial-based PDRN that is biologically active. Exosomes also; we can argue about the biological source and what is most active in the skin, but If we start looking at plant-derived exosomes, those also have human applications, maybe not as effective as human-sourced, but they solve a lot of regulatory issues as well when we go to plants. And then in terms of the epigenome, we know strictly from basic science that if we're able to turn on and off genes by affecting the DNA methyltransferases in the epigenome or the histone acetyltransferases, we could have some pretty profound changes that could extend the longevity of skin health.
How should clinicians evaluate the growing number of “cutting-edge” skincare ingredients, particularly when long-term safety and standardized protocols are still evolving?
Dr Lain: As skincare ingredients become more biologically active and we don't have a functioning FDA to oversee the safety of these new ingredients, it's really up to industry, and unfortunately, industry doesn't do a great job of policing itself. So, dermatologists themselves, ourselves as a society, we really need to be doing the hard work, the heavy lifting to determine what's safe for our patients. Also, to help direct industry, and what we believe, are the most exciting technologies or the exciting pathways that could both be helpful to our patients but also ensure safety.
What role do mechanisms like epigenetic modulation and cellular signaling pathways play in the future of anti-aging skincare, and how might this shift current treatment paradigms?
Dr Lain: Well, first of all, I think we need to stop using the term anti-aging. I think we really need to shift to a more longevity-focused approach to skin care, where, instead of reversing age we are now managing age as a disease and trying to slow it down and harness the benefits of regenerative and longevity techniques and technologies to keep ourselves as young as possible, in terms of telomere length, for example, or epigenetic alteration, but also functioning as efficiently as possible. That's where these new ingredients come in, and it's going to have to be dealt with with the change of lens and a framework change as well. We're going to have to start thinking about different biomarkers and clinical endpoints to ensure that, again, safety is paramount, but also ensure that we are hitting the longevity endpoints and not just the clinical endpoints.
